G. Mazariegos, H. Morton, K. Strauss, R. Squires, D. Finegold, M. Virgi, L. Cropcho, Erik Puffenberger, W. McGhee, L. Seward, R. Sindhi. Starzl Transplantation Institute, Pittsburgh, PA; Transplant Surgery, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA; Clinic for Special Children, Strasburg, PA.
Aim: Case reports of cure of MSUD by LT prompted a systematic evaluation of the effects of LT in these patients.
Methods: Preoperative protocol included minimization of pre-transplant fasting, dextrose infusion rates > 7 mg/kg-min to suppress endogenous protein catabolism, and strict sodium and water homeostasis. Amino acid profiles (AAP) were sent at baseline and regularly post LT with dietary protein intake recorded.
Results: 6 children (age 1.98.4 years) with severe, or Classical, biochemical phenotype underwent LT. Patient 1 was transplanted for hypervitaminosis A-associated liver failure. The five younger patients were electively transplanted to achieve metabolic cure. All patients are alive and well with follow-up from 3 months to 7.5 years. AAPs on an unrestricted diet were available for Pt #1 for >100 month follow-up. All leucine, isoleucine, and valine levels normalized immediately post LT and maintained normal parameters despite an unrestricted protein intake. Metabolic cure was documented by 1) a sustained increase in weight-adjusted leucine tolerance from 1520 mg/kg-day to > 150 mg/kg-day 2) normalization of molar ratios among the BCAAs, demonstrating in vivo regulation of amino acid oxidation rates (FIG. 1), and 3) metabolic stability during intercurrent illnesses.
Conclusion: This series of children successfully transplanted for MSUD demonstrates metabolic cure, with removal of dietary restrictions and complete protection from decompensation during illness. Preliminary observations suggest an improvement in long-term neurodevelopmental outcome that will be confirmed by prospective evaluation.
Top Updated 9/14/07